MRNA

AI Research

Mixed signals → mRNA cancer vaccine progress offset by $2.8B net losses and 3 Sell ratings

Moderna reported Q4 2025 EPS of -$2.11 and revenue of $678M (beating -$2.62 and $662.84M forecasts), supported by progress in mRNA cancer vaccines and combination vaccine favorable regulatory opinion. However, 2025 net losses reached $2.8B despite projections for 10% revenue growth in 2026 with $5.5-6B year-end cash. The stock faces 3 Buy and 3 Sell analyst ratings (Neutral consensus) with $42.90 average price target.

Related News